nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—Crohn's disease—colon cancer	0.315	0.585	CtDrD
Mesalazine—ulcerative colitis—colon cancer	0.223	0.415	CtDrD
Mesalazine—PPARG—colon cancer	0.213	0.703	CbGaD
Mesalazine—PTGS2—colon cancer	0.0899	0.297	CbGaD
Mesalazine—MPO—superior mesenteric artery—colon cancer	0.0134	0.317	CbGeAlD
Mesalazine—PPARG—Topotecan—Irinotecan—colon cancer	0.0016	1	CbGdCrCtD
Mesalazine—MPO—endothelium—colon cancer	0.00121	0.0286	CbGeAlD
Mesalazine—CHUK—epithelium—colon cancer	0.00114	0.027	CbGeAlD
Mesalazine—MPO—blood vessel—colon cancer	0.00112	0.0264	CbGeAlD
Mesalazine—PPARG—endothelium—colon cancer	0.00108	0.0254	CbGeAlD
Mesalazine—CHUK—renal system—colon cancer	0.00106	0.025	CbGeAlD
Mesalazine—PPARG—blood vessel—colon cancer	0.000992	0.0234	CbGeAlD
Mesalazine—IKBKB—embryo—colon cancer	0.000951	0.0225	CbGeAlD
Mesalazine—CHUK—lymphoid tissue—colon cancer	0.00088	0.0208	CbGeAlD
Mesalazine—CHUK—digestive system—colon cancer	0.000869	0.0205	CbGeAlD
Mesalazine—IKBKB—smooth muscle tissue—colon cancer	0.000748	0.0177	CbGeAlD
Mesalazine—CHUK—liver—colon cancer	0.000647	0.0153	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—colon cancer	0.00062	0.0146	CbGeAlD
Mesalazine—IKBKB—lymphoid tissue—colon cancer	0.000598	0.0141	CbGeAlD
Mesalazine—PPARG—embryo—colon cancer	0.000592	0.014	CbGeAlD
Mesalazine—IKBKB—digestive system—colon cancer	0.000591	0.0139	CbGeAlD
Mesalazine—PTGS1—endothelium—colon cancer	0.000575	0.0136	CbGeAlD
Mesalazine—Olsalazine—PPARG—colon cancer	0.000551	0.309	CrCbGaD
Mesalazine—PTGS2—endothelium—colon cancer	0.00055	0.013	CbGeAlD
Mesalazine—MPO—epithelium—colon cancer	0.000544	0.0129	CbGeAlD
Mesalazine—PTGS1—blood vessel—colon cancer	0.000531	0.0125	CbGeAlD
Mesalazine—IKBKB—vagina—colon cancer	0.000522	0.0123	CbGeAlD
Mesalazine—PTGS2—blood vessel—colon cancer	0.000507	0.012	CbGeAlD
Mesalazine—MPO—renal system—colon cancer	0.000505	0.0119	CbGeAlD
Mesalazine—CHUK—lymph node—colon cancer	0.000496	0.0117	CbGeAlD
Mesalazine—ALOX5—lymphoid tissue—colon cancer	0.000496	0.0117	CbGeAlD
Mesalazine—ALOX5—digestive system—colon cancer	0.000489	0.0116	CbGeAlD
Mesalazine—PPARG—epithelium—colon cancer	0.000483	0.0114	CbGeAlD
Mesalazine—PTGS2—gall bladder—colon cancer	0.000477	0.0113	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—colon cancer	0.000465	0.011	CbGeAlD
Mesalazine—ALOX5—bone marrow—colon cancer	0.000451	0.0107	CbGeAlD
Mesalazine—PPARG—renal system—colon cancer	0.000448	0.0106	CbGeAlD
Mesalazine—IKBKB—liver—colon cancer	0.00044	0.0104	CbGeAlD
Mesalazine—MPO—lymphoid tissue—colon cancer	0.000419	0.0099	CbGeAlD
Mesalazine—MPO—digestive system—colon cancer	0.000414	0.00978	CbGeAlD
Mesalazine—MPO—bone marrow—colon cancer	0.000382	0.00902	CbGeAlD
Mesalazine—PPARG—lymphoid tissue—colon cancer	0.000372	0.00879	CbGeAlD
Mesalazine—PPARG—digestive system—colon cancer	0.000368	0.00868	CbGeAlD
Mesalazine—ALOX5—liver—colon cancer	0.000365	0.00861	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—colon cancer	0.000339	0.19	CrCbGaD
Mesalazine—PPARG—bone marrow—colon cancer	0.000339	0.008	CbGeAlD
Mesalazine—IKBKB—lymph node—colon cancer	0.000337	0.00797	CbGeAlD
Mesalazine—PPARG—vagina—colon cancer	0.000325	0.00767	CbGeAlD
Mesalazine—MPO—liver—colon cancer	0.000309	0.00729	CbGeAlD
Mesalazine—PTGS2—embryo—colon cancer	0.000302	0.00714	CbGeAlD
Mesalazine—ALOX5—lymph node—colon cancer	0.00028	0.0066	CbGeAlD
Mesalazine—PPARG—liver—colon cancer	0.000274	0.00647	CbGeAlD
Mesalazine—PTGS1—epithelium—colon cancer	0.000258	0.0061	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—colon cancer	0.000249	0.00588	CbGeAlD
Mesalazine—PTGS2—epithelium—colon cancer	0.000247	0.00583	CbGeAlD
Mesalazine—PTGS1—renal system—colon cancer	0.00024	0.00566	CbGeAlD
Mesalazine—PTGS2—smooth muscle tissue—colon cancer	0.000238	0.00562	CbGeAlD
Mesalazine—MPO—lymph node—colon cancer	0.000237	0.00559	CbGeAlD
Mesalazine—Olsalazine—PTGS2—colon cancer	0.000233	0.13	CrCbGaD
Mesalazine—PTGS2—renal system—colon cancer	0.000229	0.00541	CbGeAlD
Mesalazine—Aminosalicylic Acid—PTGS2—colon cancer	0.000219	0.122	CrCbGaD
Mesalazine—Diflunisal—PTGS2—colon cancer	0.000219	0.122	CrCbGaD
Mesalazine—PPARG—lymph node—colon cancer	0.00021	0.00496	CbGeAlD
Mesalazine—PTGS1—digestive system—colon cancer	0.000196	0.00464	CbGeAlD
Mesalazine—PTGS2—lymphoid tissue—colon cancer	0.00019	0.00449	CbGeAlD
Mesalazine—PTGS2—digestive system—colon cancer	0.000188	0.00444	CbGeAlD
Mesalazine—PTGS1—vagina—colon cancer	0.000174	0.0041	CbGeAlD
Mesalazine—PTGS2—bone marrow—colon cancer	0.000173	0.00409	CbGeAlD
Mesalazine—PTGS2—vagina—colon cancer	0.000166	0.00392	CbGeAlD
Mesalazine—PTGS2—liver—colon cancer	0.00014	0.0033	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—colon cancer	0.000122	0.0681	CrCbGaD
Mesalazine—PTGS1—lymph node—colon cancer	0.000112	0.00265	CbGeAlD
Mesalazine—PTGS2—lymph node—colon cancer	0.000107	0.00253	CbGeAlD
Mesalazine—Salicylic acid—ABCB1—colon cancer	0.000103	0.0579	CrCbGaD
Mesalazine—Nervous system disorder—Irinotecan—colon cancer	7.09e-05	0.00108	CcSEcCtD
Mesalazine—Agranulocytosis—Capecitabine—colon cancer	7.08e-05	0.00108	CcSEcCtD
Mesalazine—Thrombocytopenia—Irinotecan—colon cancer	7.08e-05	0.00108	CcSEcCtD
Mesalazine—Anorexia—Vincristine—colon cancer	7.07e-05	0.00108	CcSEcCtD
Mesalazine—Hyperhidrosis—Irinotecan—colon cancer	6.99e-05	0.00106	CcSEcCtD
Mesalazine—Confusional state—Fluorouracil—colon cancer	6.98e-05	0.00106	CcSEcCtD
Mesalazine—Mood swings—Methotrexate—colon cancer	6.94e-05	0.00106	CcSEcCtD
Mesalazine—Hypotension—Vincristine—colon cancer	6.93e-05	0.00106	CcSEcCtD
Mesalazine—Anaphylactic shock—Fluorouracil—colon cancer	6.92e-05	0.00105	CcSEcCtD
Mesalazine—Oedema—Fluorouracil—colon cancer	6.92e-05	0.00105	CcSEcCtD
Mesalazine—Anorexia—Irinotecan—colon cancer	6.89e-05	0.00105	CcSEcCtD
Mesalazine—Infection—Fluorouracil—colon cancer	6.88e-05	0.00105	CcSEcCtD
Mesalazine—Haemoglobin—Capecitabine—colon cancer	6.84e-05	0.00104	CcSEcCtD
Mesalazine—Rhinitis—Capecitabine—colon cancer	6.83e-05	0.00104	CcSEcCtD
Mesalazine—Haemorrhage—Capecitabine—colon cancer	6.81e-05	0.00104	CcSEcCtD
Mesalazine—Hepatitis—Capecitabine—colon cancer	6.81e-05	0.00104	CcSEcCtD
Mesalazine—Nervous system disorder—Fluorouracil—colon cancer	6.79e-05	0.00103	CcSEcCtD
Mesalazine—Thrombocytopenia—Fluorouracil—colon cancer	6.78e-05	0.00103	CcSEcCtD
Mesalazine—Liver function test abnormal—Methotrexate—colon cancer	6.76e-05	0.00103	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Vincristine—colon cancer	6.76e-05	0.00103	CcSEcCtD
Mesalazine—Pharyngitis—Capecitabine—colon cancer	6.76e-05	0.00103	CcSEcCtD
Mesalazine—Tachycardia—Fluorouracil—colon cancer	6.76e-05	0.00103	CcSEcCtD
Mesalazine—Hypotension—Irinotecan—colon cancer	6.75e-05	0.00103	CcSEcCtD
Mesalazine—Urinary tract disorder—Capecitabine—colon cancer	6.72e-05	0.00102	CcSEcCtD
Mesalazine—Insomnia—Vincristine—colon cancer	6.71e-05	0.00102	CcSEcCtD
Mesalazine—Oedema peripheral—Capecitabine—colon cancer	6.71e-05	0.00102	CcSEcCtD
Mesalazine—Connective tissue disorder—Capecitabine—colon cancer	6.69e-05	0.00102	CcSEcCtD
Mesalazine—Urethral disorder—Capecitabine—colon cancer	6.67e-05	0.00102	CcSEcCtD
Mesalazine—Paraesthesia—Vincristine—colon cancer	6.66e-05	0.00102	CcSEcCtD
Mesalazine—Breast disorder—Methotrexate—colon cancer	6.62e-05	0.00101	CcSEcCtD
Mesalazine—Anorexia—Fluorouracil—colon cancer	6.6e-05	0.00101	CcSEcCtD
Mesalazine—Insomnia—Irinotecan—colon cancer	6.54e-05	0.000996	CcSEcCtD
Mesalazine—Paraesthesia—Irinotecan—colon cancer	6.49e-05	0.000989	CcSEcCtD
Mesalazine—Hypotension—Fluorouracil—colon cancer	6.47e-05	0.000986	CcSEcCtD
Mesalazine—Decreased appetite—Vincristine—colon cancer	6.45e-05	0.000983	CcSEcCtD
Mesalazine—Dyspnoea—Irinotecan—colon cancer	6.44e-05	0.000982	CcSEcCtD
Mesalazine—Erythema multiforme—Capecitabine—colon cancer	6.44e-05	0.000981	CcSEcCtD
Mesalazine—Somnolence—Irinotecan—colon cancer	6.42e-05	0.000979	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Vincristine—colon cancer	6.41e-05	0.000976	CcSEcCtD
Mesalazine—Fatigue—Vincristine—colon cancer	6.4e-05	0.000975	CcSEcCtD
Mesalazine—Eye disorder—Capecitabine—colon cancer	6.36e-05	0.000969	CcSEcCtD
Mesalazine—Dyspepsia—Irinotecan—colon cancer	6.36e-05	0.000969	CcSEcCtD
Mesalazine—Tinnitus—Capecitabine—colon cancer	6.35e-05	0.000967	CcSEcCtD
Mesalazine—Constipation—Vincristine—colon cancer	6.35e-05	0.000967	CcSEcCtD
Mesalazine—Pain—Vincristine—colon cancer	6.35e-05	0.000967	CcSEcCtD
Mesalazine—Asthma—Methotrexate—colon cancer	6.33e-05	0.000965	CcSEcCtD
Mesalazine—Cardiac disorder—Capecitabine—colon cancer	6.32e-05	0.000963	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Fluorouracil—colon cancer	6.31e-05	0.000961	CcSEcCtD
Mesalazine—Decreased appetite—Irinotecan—colon cancer	6.28e-05	0.000957	CcSEcCtD
Mesalazine—Eosinophilia—Methotrexate—colon cancer	6.27e-05	0.000955	CcSEcCtD
Mesalazine—Insomnia—Fluorouracil—colon cancer	6.26e-05	0.000954	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Irinotecan—colon cancer	6.24e-05	0.000951	CcSEcCtD
Mesalazine—Fatigue—Irinotecan—colon cancer	6.23e-05	0.000949	CcSEcCtD
Mesalazine—Paraesthesia—Fluorouracil—colon cancer	6.22e-05	0.000947	CcSEcCtD
Mesalazine—Pancreatitis—Methotrexate—colon cancer	6.21e-05	0.000946	CcSEcCtD
Mesalazine—Pain—Irinotecan—colon cancer	6.18e-05	0.000942	CcSEcCtD
Mesalazine—Constipation—Irinotecan—colon cancer	6.18e-05	0.000942	CcSEcCtD
Mesalazine—Angiopathy—Capecitabine—colon cancer	6.18e-05	0.000941	CcSEcCtD
Mesalazine—Dyspnoea—Fluorouracil—colon cancer	6.17e-05	0.00094	CcSEcCtD
Mesalazine—Somnolence—Fluorouracil—colon cancer	6.15e-05	0.000938	CcSEcCtD
Mesalazine—Immune system disorder—Capecitabine—colon cancer	6.15e-05	0.000937	CcSEcCtD
Mesalazine—Mediastinal disorder—Capecitabine—colon cancer	6.14e-05	0.000935	CcSEcCtD
Mesalazine—Chills—Capecitabine—colon cancer	6.11e-05	0.000931	CcSEcCtD
Mesalazine—Dyspepsia—Fluorouracil—colon cancer	6.09e-05	0.000928	CcSEcCtD
Mesalazine—Abdominal discomfort—Methotrexate—colon cancer	6.07e-05	0.000925	CcSEcCtD
Mesalazine—Gastrointestinal pain—Vincristine—colon cancer	6.07e-05	0.000925	CcSEcCtD
Mesalazine—Decreased appetite—Fluorouracil—colon cancer	6.02e-05	0.000917	CcSEcCtD
Mesalazine—Alopecia—Capecitabine—colon cancer	6.02e-05	0.000917	CcSEcCtD
Mesalazine—Pancytopenia—Methotrexate—colon cancer	6.01e-05	0.000916	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Fluorouracil—colon cancer	5.98e-05	0.000911	CcSEcCtD
Mesalazine—Mental disorder—Capecitabine—colon cancer	5.96e-05	0.000909	CcSEcCtD
Mesalazine—Feeling abnormal—Irinotecan—colon cancer	5.96e-05	0.000907	CcSEcCtD
Mesalazine—Erythema—Capecitabine—colon cancer	5.93e-05	0.000903	CcSEcCtD
Mesalazine—Neutropenia—Methotrexate—colon cancer	5.92e-05	0.000902	CcSEcCtD
Mesalazine—Dysuria—Methotrexate—colon cancer	5.92e-05	0.000902	CcSEcCtD
Mesalazine—Pain—Fluorouracil—colon cancer	5.92e-05	0.000902	CcSEcCtD
Mesalazine—Gastrointestinal pain—Irinotecan—colon cancer	5.91e-05	0.0009	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Methotrexate—colon cancer	5.88e-05	0.000897	CcSEcCtD
Mesalazine—Abdominal pain—Vincristine—colon cancer	5.87e-05	0.000894	CcSEcCtD
Mesalazine—Body temperature increased—Vincristine—colon cancer	5.87e-05	0.000894	CcSEcCtD
Mesalazine—Flatulence—Capecitabine—colon cancer	5.84e-05	0.00089	CcSEcCtD
Mesalazine—Dysgeusia—Capecitabine—colon cancer	5.8e-05	0.000884	CcSEcCtD
Mesalazine—Photosensitivity reaction—Methotrexate—colon cancer	5.78e-05	0.000881	CcSEcCtD
Mesalazine—Back pain—Capecitabine—colon cancer	5.73e-05	0.000874	CcSEcCtD
Mesalazine—Abdominal pain—Irinotecan—colon cancer	5.71e-05	0.000871	CcSEcCtD
Mesalazine—Body temperature increased—Irinotecan—colon cancer	5.71e-05	0.000871	CcSEcCtD
Mesalazine—Feeling abnormal—Fluorouracil—colon cancer	5.7e-05	0.000869	CcSEcCtD
Mesalazine—Muscle spasms—Capecitabine—colon cancer	5.7e-05	0.000868	CcSEcCtD
Mesalazine—Pneumonia—Methotrexate—colon cancer	5.68e-05	0.000865	CcSEcCtD
Mesalazine—Infestation NOS—Methotrexate—colon cancer	5.65e-05	0.00086	CcSEcCtD
Mesalazine—Infestation—Methotrexate—colon cancer	5.65e-05	0.00086	CcSEcCtD
Mesalazine—Depression—Methotrexate—colon cancer	5.63e-05	0.000858	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Methotrexate—colon cancer	5.6e-05	0.000853	CcSEcCtD
Mesalazine—Vision blurred—Capecitabine—colon cancer	5.59e-05	0.000851	CcSEcCtD
Mesalazine—Tremor—Capecitabine—colon cancer	5.55e-05	0.000846	CcSEcCtD
Mesalazine—Renal failure—Methotrexate—colon cancer	5.55e-05	0.000846	CcSEcCtD
Mesalazine—Stomatitis—Methotrexate—colon cancer	5.5e-05	0.000839	CcSEcCtD
Mesalazine—Ill-defined disorder—Capecitabine—colon cancer	5.5e-05	0.000838	CcSEcCtD
Mesalazine—Urticaria—Fluorouracil—colon cancer	5.5e-05	0.000838	CcSEcCtD
Mesalazine—Conjunctivitis—Methotrexate—colon cancer	5.49e-05	0.000836	CcSEcCtD
Mesalazine—Anaemia—Capecitabine—colon cancer	5.48e-05	0.000835	CcSEcCtD
Mesalazine—Body temperature increased—Fluorouracil—colon cancer	5.47e-05	0.000834	CcSEcCtD
Mesalazine—Hypersensitivity—Vincristine—colon cancer	5.47e-05	0.000833	CcSEcCtD
Mesalazine—Sweating—Methotrexate—colon cancer	5.41e-05	0.000825	CcSEcCtD
Mesalazine—Haematuria—Methotrexate—colon cancer	5.38e-05	0.00082	CcSEcCtD
Mesalazine—Malaise—Capecitabine—colon cancer	5.34e-05	0.000814	CcSEcCtD
Mesalazine—Hepatobiliary disease—Methotrexate—colon cancer	5.34e-05	0.000814	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—colon cancer	5.32e-05	0.000811	CcSEcCtD
Mesalazine—Vertigo—Capecitabine—colon cancer	5.32e-05	0.000811	CcSEcCtD
Mesalazine—Hypersensitivity—Irinotecan—colon cancer	5.32e-05	0.000811	CcSEcCtD
Mesalazine—Asthenia—Vincristine—colon cancer	5.32e-05	0.000811	CcSEcCtD
Mesalazine—Syncope—Capecitabine—colon cancer	5.31e-05	0.00081	CcSEcCtD
Mesalazine—Leukopenia—Capecitabine—colon cancer	5.3e-05	0.000808	CcSEcCtD
Mesalazine—Agranulocytosis—Methotrexate—colon cancer	5.27e-05	0.000803	CcSEcCtD
Mesalazine—Palpitations—Capecitabine—colon cancer	5.24e-05	0.000798	CcSEcCtD
Mesalazine—Loss of consciousness—Capecitabine—colon cancer	5.21e-05	0.000794	CcSEcCtD
Mesalazine—Asthenia—Irinotecan—colon cancer	5.19e-05	0.00079	CcSEcCtD
Mesalazine—Cough—Capecitabine—colon cancer	5.17e-05	0.000788	CcSEcCtD
Mesalazine—Hypertension—Capecitabine—colon cancer	5.12e-05	0.00078	CcSEcCtD
Mesalazine—Hypersensitivity—Fluorouracil—colon cancer	5.1e-05	0.000777	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—colon cancer	5.09e-05	0.000776	CcSEcCtD
Mesalazine—Diarrhoea—Vincristine—colon cancer	5.08e-05	0.000774	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—colon cancer	5.07e-05	0.000772	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—colon cancer	5.07e-05	0.000772	CcSEcCtD
Mesalazine—Chest pain—Capecitabine—colon cancer	5.05e-05	0.000769	CcSEcCtD
Mesalazine—Arthralgia—Capecitabine—colon cancer	5.05e-05	0.000769	CcSEcCtD
Mesalazine—Myalgia—Capecitabine—colon cancer	5.05e-05	0.000769	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—colon cancer	5.03e-05	0.000766	CcSEcCtD
Mesalazine—Anxiety—Capecitabine—colon cancer	5.03e-05	0.000766	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	5.01e-05	0.000764	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—colon cancer	5.01e-05	0.000763	CcSEcCtD
Mesalazine—Discomfort—Capecitabine—colon cancer	4.99e-05	0.00076	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—colon cancer	4.97e-05	0.000757	CcSEcCtD
Mesalazine—Diarrhoea—Irinotecan—colon cancer	4.94e-05	0.000753	CcSEcCtD
Mesalazine—Dry mouth—Capecitabine—colon cancer	4.93e-05	0.000752	CcSEcCtD
Mesalazine—Dizziness—Vincristine—colon cancer	4.91e-05	0.000748	CcSEcCtD
Mesalazine—Pruritus—Fluorouracil—colon cancer	4.9e-05	0.000746	CcSEcCtD
Mesalazine—Confusional state—Capecitabine—colon cancer	4.88e-05	0.000743	CcSEcCtD
Mesalazine—Oedema—Capecitabine—colon cancer	4.84e-05	0.000737	CcSEcCtD
Mesalazine—Infection—Capecitabine—colon cancer	4.81e-05	0.000732	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—colon cancer	4.79e-05	0.00073	CcSEcCtD
Mesalazine—Dizziness—Irinotecan—colon cancer	4.78e-05	0.000728	CcSEcCtD
Mesalazine—Shock—Capecitabine—colon cancer	4.76e-05	0.000725	CcSEcCtD
Mesalazine—Nervous system disorder—Capecitabine—colon cancer	4.74e-05	0.000723	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—colon cancer	4.74e-05	0.000722	CcSEcCtD
Mesalazine—Diarrhoea—Fluorouracil—colon cancer	4.74e-05	0.000722	CcSEcCtD
Mesalazine—Thrombocytopenia—Capecitabine—colon cancer	4.74e-05	0.000722	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—colon cancer	4.73e-05	0.00072	CcSEcCtD
Mesalazine—Tachycardia—Capecitabine—colon cancer	4.72e-05	0.000719	CcSEcCtD
Mesalazine—Vomiting—Vincristine—colon cancer	4.72e-05	0.000719	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—colon cancer	4.7e-05	0.000717	CcSEcCtD
Mesalazine—Skin disorder—Capecitabine—colon cancer	4.7e-05	0.000716	CcSEcCtD
Mesalazine—Rash—Vincristine—colon cancer	4.68e-05	0.000713	CcSEcCtD
Mesalazine—Hyperhidrosis—Capecitabine—colon cancer	4.68e-05	0.000713	CcSEcCtD
Mesalazine—Dermatitis—Vincristine—colon cancer	4.67e-05	0.000712	CcSEcCtD
Mesalazine—Headache—Vincristine—colon cancer	4.65e-05	0.000708	CcSEcCtD
Mesalazine—Anorexia—Capecitabine—colon cancer	4.61e-05	0.000703	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—colon cancer	4.6e-05	0.000701	CcSEcCtD
Mesalazine—Vomiting—Irinotecan—colon cancer	4.59e-05	0.0007	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—colon cancer	4.58e-05	0.000698	CcSEcCtD
Mesalazine—Dizziness—Fluorouracil—colon cancer	4.58e-05	0.000697	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—colon cancer	4.57e-05	0.000696	CcSEcCtD
Mesalazine—Rash—Irinotecan—colon cancer	4.56e-05	0.000694	CcSEcCtD
Mesalazine—Dermatitis—Irinotecan—colon cancer	4.55e-05	0.000694	CcSEcCtD
Mesalazine—Chills—Methotrexate—colon cancer	4.55e-05	0.000693	CcSEcCtD
Mesalazine—Headache—Irinotecan—colon cancer	4.53e-05	0.00069	CcSEcCtD
Mesalazine—Hypotension—Capecitabine—colon cancer	4.52e-05	0.000689	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—colon cancer	4.48e-05	0.000682	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—colon cancer	4.44e-05	0.000677	CcSEcCtD
Mesalazine—Erythema—Methotrexate—colon cancer	4.41e-05	0.000672	CcSEcCtD
Mesalazine—Nausea—Vincristine—colon cancer	4.41e-05	0.000672	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Capecitabine—colon cancer	4.41e-05	0.000671	CcSEcCtD
Mesalazine—Vomiting—Fluorouracil—colon cancer	4.4e-05	0.000671	CcSEcCtD
Mesalazine—Insomnia—Capecitabine—colon cancer	4.37e-05	0.000667	CcSEcCtD
Mesalazine—Rash—Fluorouracil—colon cancer	4.36e-05	0.000665	CcSEcCtD
Mesalazine—Dermatitis—Fluorouracil—colon cancer	4.36e-05	0.000664	CcSEcCtD
Mesalazine—Paraesthesia—Capecitabine—colon cancer	4.34e-05	0.000662	CcSEcCtD
Mesalazine—Headache—Fluorouracil—colon cancer	4.34e-05	0.000661	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—colon cancer	4.32e-05	0.000658	CcSEcCtD
Mesalazine—Dyspnoea—Capecitabine—colon cancer	4.31e-05	0.000657	CcSEcCtD
Mesalazine—Nausea—Irinotecan—colon cancer	4.29e-05	0.000654	CcSEcCtD
Mesalazine—Back pain—Methotrexate—colon cancer	4.27e-05	0.00065	CcSEcCtD
Mesalazine—Dyspepsia—Capecitabine—colon cancer	4.26e-05	0.000649	CcSEcCtD
Mesalazine—Decreased appetite—Capecitabine—colon cancer	4.2e-05	0.000641	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Capecitabine—colon cancer	4.18e-05	0.000636	CcSEcCtD
Mesalazine—Fatigue—Capecitabine—colon cancer	4.17e-05	0.000635	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—colon cancer	4.16e-05	0.000634	CcSEcCtD
Mesalazine—Pain—Capecitabine—colon cancer	4.14e-05	0.00063	CcSEcCtD
Mesalazine—Constipation—Capecitabine—colon cancer	4.14e-05	0.00063	CcSEcCtD
Mesalazine—Nausea—Fluorouracil—colon cancer	4.11e-05	0.000626	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—colon cancer	4.09e-05	0.000624	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—colon cancer	4.08e-05	0.000621	CcSEcCtD
Mesalazine—Feeling abnormal—Capecitabine—colon cancer	3.99e-05	0.000607	CcSEcCtD
Mesalazine—Malaise—Methotrexate—colon cancer	3.98e-05	0.000606	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—colon cancer	3.96e-05	0.000604	CcSEcCtD
Mesalazine—Gastrointestinal pain—Capecitabine—colon cancer	3.96e-05	0.000603	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—colon cancer	3.95e-05	0.000602	CcSEcCtD
Mesalazine—Cough—Methotrexate—colon cancer	3.85e-05	0.000587	CcSEcCtD
Mesalazine—Urticaria—Capecitabine—colon cancer	3.84e-05	0.000586	CcSEcCtD
Mesalazine—Body temperature increased—Capecitabine—colon cancer	3.82e-05	0.000583	CcSEcCtD
Mesalazine—Abdominal pain—Capecitabine—colon cancer	3.82e-05	0.000583	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—colon cancer	3.76e-05	0.000572	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—colon cancer	3.76e-05	0.000572	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—colon cancer	3.76e-05	0.000572	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	3.73e-05	0.000568	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—colon cancer	3.71e-05	0.000565	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—colon cancer	3.63e-05	0.000553	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—colon cancer	3.6e-05	0.000549	CcSEcCtD
Mesalazine—Infection—Methotrexate—colon cancer	3.58e-05	0.000545	CcSEcCtD
Mesalazine—Hypersensitivity—Capecitabine—colon cancer	3.56e-05	0.000543	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—colon cancer	3.53e-05	0.000538	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—colon cancer	3.53e-05	0.000537	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—colon cancer	3.5e-05	0.000533	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—colon cancer	3.48e-05	0.00053	CcSEcCtD
Mesalazine—Asthenia—Capecitabine—colon cancer	3.47e-05	0.000529	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—colon cancer	3.43e-05	0.000523	CcSEcCtD
Mesalazine—Pruritus—Capecitabine—colon cancer	3.42e-05	0.000521	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—colon cancer	3.36e-05	0.000513	CcSEcCtD
Mesalazine—Diarrhoea—Capecitabine—colon cancer	3.31e-05	0.000504	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—colon cancer	3.28e-05	0.0005	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—colon cancer	3.26e-05	0.000496	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—colon cancer	3.23e-05	0.000493	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—colon cancer	3.21e-05	0.000489	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—colon cancer	3.2e-05	0.000488	CcSEcCtD
Mesalazine—Dizziness—Capecitabine—colon cancer	3.2e-05	0.000487	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—colon cancer	3.17e-05	0.000483	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—colon cancer	3.13e-05	0.000477	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—colon cancer	3.11e-05	0.000474	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—colon cancer	3.1e-05	0.000473	CcSEcCtD
Mesalazine—Pain—Methotrexate—colon cancer	3.08e-05	0.000469	CcSEcCtD
Mesalazine—Vomiting—Capecitabine—colon cancer	3.08e-05	0.000469	CcSEcCtD
Mesalazine—Rash—Capecitabine—colon cancer	3.05e-05	0.000465	CcSEcCtD
Mesalazine—Dermatitis—Capecitabine—colon cancer	3.05e-05	0.000464	CcSEcCtD
Mesalazine—Headache—Capecitabine—colon cancer	3.03e-05	0.000462	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—colon cancer	2.97e-05	0.000452	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—colon cancer	2.94e-05	0.000449	CcSEcCtD
Mesalazine—Nausea—Capecitabine—colon cancer	2.87e-05	0.000438	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—colon cancer	2.86e-05	0.000436	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—colon cancer	2.85e-05	0.000434	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—colon cancer	2.85e-05	0.000434	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—colon cancer	2.65e-05	0.000404	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—colon cancer	2.58e-05	0.000394	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—colon cancer	2.55e-05	0.000388	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—colon cancer	2.46e-05	0.000375	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—colon cancer	2.38e-05	0.000363	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—colon cancer	2.29e-05	0.000349	CcSEcCtD
Mesalazine—Rash—Methotrexate—colon cancer	2.27e-05	0.000346	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—colon cancer	2.27e-05	0.000346	CcSEcCtD
Mesalazine—Headache—Methotrexate—colon cancer	2.26e-05	0.000344	CcSEcCtD
Mesalazine—Nausea—Methotrexate—colon cancer	2.14e-05	0.000326	CcSEcCtD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—HRAS—colon cancer	2e-05	0.000426	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—TYMS—colon cancer	2e-05	0.000426	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—CDKN1A—colon cancer	2e-05	0.000425	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—AKT1—colon cancer	2e-05	0.000425	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NRAS—colon cancer	2e-05	0.000425	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—AKT1—colon cancer	1.99e-05	0.000424	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—AKT1—colon cancer	1.99e-05	0.000423	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—FGFR3—colon cancer	1.98e-05	0.000422	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—AKT1—colon cancer	1.98e-05	0.000421	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—NRAS—colon cancer	1.96e-05	0.000418	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—BCL2L1—colon cancer	1.96e-05	0.000417	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—HRAS—colon cancer	1.95e-05	0.000415	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—colon cancer	1.95e-05	0.000415	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.91e-05	0.000408	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—PIK3CA—colon cancer	1.91e-05	0.000407	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—HRAS—colon cancer	1.91e-05	0.000407	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—FGFR3—colon cancer	1.87e-05	0.000398	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	1.87e-05	0.000397	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.86e-05	0.000397	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—AKT1—colon cancer	1.86e-05	0.000396	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	1.86e-05	0.000396	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—AKT1—colon cancer	1.86e-05	0.000396	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—SRC—colon cancer	1.85e-05	0.000394	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.85e-05	0.000393	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—AKT1—colon cancer	1.84e-05	0.000393	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—AKT1—colon cancer	1.83e-05	0.000389	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—AKT1—colon cancer	1.83e-05	0.000389	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—AKT1—colon cancer	1.82e-05	0.000387	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NRAS—colon cancer	1.81e-05	0.000385	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—colon cancer	1.8e-05	0.000384	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.8e-05	0.000384	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—FGFR3—colon cancer	1.8e-05	0.000382	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—EGFR—colon cancer	1.79e-05	0.000381	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—NRAS—colon cancer	1.78e-05	0.000379	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—colon cancer	1.77e-05	0.000376	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—colon cancer	1.77e-05	0.000376	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—AKT1—colon cancer	1.76e-05	0.000374	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.75e-05	0.000373	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—AKT1—colon cancer	1.72e-05	0.000367	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—KRAS—colon cancer	1.72e-05	0.000366	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.72e-05	0.000365	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—KRAS—colon cancer	1.69e-05	0.000359	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	1.69e-05	0.000359	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDH1—colon cancer	1.67e-05	0.000356	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.67e-05	0.000355	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	1.65e-05	0.000351	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.62e-05	0.000346	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—EGFR—colon cancer	1.62e-05	0.000345	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—PIK3CA—colon cancer	1.58e-05	0.000336	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—AKT1—colon cancer	1.56e-05	0.000332	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—KRAS—colon cancer	1.56e-05	0.000332	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—CTNNB1—colon cancer	1.55e-05	0.00033	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—PIK3CA—colon cancer	1.55e-05	0.00033	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.55e-05	0.00033	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.54e-05	0.000328	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—KRAS—colon cancer	1.53e-05	0.000326	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDH1—colon cancer	1.52e-05	0.000323	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.49e-05	0.000318	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.49e-05	0.000318	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD8A—colon cancer	1.47e-05	0.000313	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.46e-05	0.000311	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—colon cancer	1.46e-05	0.000311	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EP300—colon cancer	1.44e-05	0.000307	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—HRAS—colon cancer	1.44e-05	0.000306	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—PIK3CA—colon cancer	1.43e-05	0.000305	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PPARG—colon cancer	1.42e-05	0.000302	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PIK3CA—colon cancer	1.41e-05	0.000299	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—SRC—colon cancer	1.4e-05	0.000299	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.38e-05	0.000294	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.38e-05	0.000294	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—colon cancer	1.37e-05	0.000291	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—NRAS—colon cancer	1.35e-05	0.000287	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—colon cancer	1.34e-05	0.000284	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD8A—colon cancer	1.33e-05	0.000284	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—colon cancer	1.32e-05	0.000282	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—colon cancer	1.3e-05	0.000277	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.29e-05	0.000274	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CTNNB1—colon cancer	1.29e-05	0.000274	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.27e-05	0.00027	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—AKT1—colon cancer	1.27e-05	0.00027	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ABCB1—colon cancer	1.26e-05	0.000268	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CDKN1A—colon cancer	1.26e-05	0.000268	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2L1—colon cancer	1.26e-05	0.000268	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TGFB1—colon cancer	1.25e-05	0.000267	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TYMS—colon cancer	1.24e-05	0.000264	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—colon cancer	1.23e-05	0.000262	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.23e-05	0.000261	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDKN1A—colon cancer	1.21e-05	0.000257	CbGpPWpGaD
Mesalazine—CHUK—Immune System—FGFR3—colon cancer	1.2e-05	0.000256	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EP300—colon cancer	1.2e-05	0.000255	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CTNNB1—colon cancer	1.17e-05	0.000248	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—SRC—colon cancer	1.16e-05	0.000248	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—colon cancer	1.16e-05	0.000247	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—colon cancer	1.15e-05	0.000245	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CDKN1A—colon cancer	1.14e-05	0.000243	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2L1—colon cancer	1.14e-05	0.000243	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NRAS—colon cancer	1.12e-05	0.000238	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—SRC—colon cancer	1.12e-05	0.000238	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—colon cancer	1.11e-05	0.000237	CbGpPWpGaD
Mesalazine—CHUK—Disease—FGFR3—colon cancer	1.11e-05	0.000236	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.09e-05	0.000233	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1A—colon cancer	1.09e-05	0.000233	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FGFR3—colon cancer	1.09e-05	0.000232	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.09e-05	0.000231	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EP300—colon cancer	1.08e-05	0.000231	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—colon cancer	1.07e-05	0.000229	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—SRC—colon cancer	1.05e-05	0.000225	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.04e-05	0.000221	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—colon cancer	1.02e-05	0.000217	CbGpPWpGaD
Mesalazine—CHUK—Disease—APC—colon cancer	1.02e-05	0.000217	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—colon cancer	1.02e-05	0.000216	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRAS—colon cancer	1.01e-05	0.000216	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—SRC—colon cancer	1.01e-05	0.000216	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—colon cancer	9.87e-06	0.00021	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—colon cancer	9.79e-06	0.000208	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—colon cancer	9.74e-06	0.000207	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—colon cancer	9.63e-06	0.000205	CbGpPWpGaD
Mesalazine—CHUK—Disease—BRAF—colon cancer	9.57e-06	0.000204	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.53e-06	0.000203	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—EP300—colon cancer	9.27e-06	0.000197	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—colon cancer	9.25e-06	0.000197	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—colon cancer	9.24e-06	0.000197	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—colon cancer	9.21e-06	0.000196	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.02e-06	0.000192	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—colon cancer	8.88e-06	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—colon cancer	8.85e-06	0.000188	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ABCB1—colon cancer	8.83e-06	0.000188	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—colon cancer	8.73e-06	0.000186	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—colon cancer	8.72e-06	0.000186	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TYMS—colon cancer	8.67e-06	0.000185	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—colon cancer	8.5e-06	0.000181	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—colon cancer	8.38e-06	0.000179	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—colon cancer	8.19e-06	0.000174	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—colon cancer	8.02e-06	0.000171	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—colon cancer	7.86e-06	0.000167	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGFR3—colon cancer	7.77e-06	0.000165	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—colon cancer	7.73e-06	0.000165	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—colon cancer	7.7e-06	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—colon cancer	7.49e-06	0.00016	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—colon cancer	7.42e-06	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—colon cancer	7.32e-06	0.000156	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—colon cancer	7.23e-06	0.000154	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.16e-06	0.000153	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—colon cancer	7.13e-06	0.000152	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—colon cancer	7.13e-06	0.000152	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR3—colon cancer	7.04e-06	0.00015	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—colon cancer	7.01e-06	0.000149	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EP300—colon cancer	6.97e-06	0.000148	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—colon cancer	6.94e-06	0.000148	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—colon cancer	6.92e-06	0.000147	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—colon cancer	6.9e-06	0.000147	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—colon cancer	6.88e-06	0.000147	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—colon cancer	6.86e-06	0.000146	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—colon cancer	6.8e-06	0.000145	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—colon cancer	6.77e-06	0.000144	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—colon cancer	6.76e-06	0.000144	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—colon cancer	6.7e-06	0.000143	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.68e-06	0.000142	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—colon cancer	6.64e-06	0.000141	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR3—colon cancer	6.57e-06	0.00014	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—colon cancer	6.55e-06	0.00014	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—colon cancer	6.52e-06	0.000139	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—colon cancer	6.47e-06	0.000138	CbGpPWpGaD
Mesalazine—CHUK—Disease—EP300—colon cancer	6.43e-06	0.000137	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—colon cancer	6.43e-06	0.000137	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EP300—colon cancer	6.32e-06	0.000134	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—colon cancer	6.29e-06	0.000134	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—colon cancer	6.25e-06	0.000133	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—colon cancer	6.14e-06	0.000131	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—colon cancer	6.14e-06	0.000131	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—colon cancer	6.08e-06	0.000129	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—colon cancer	6.03e-06	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—colon cancer	6.02e-06	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—colon cancer	5.94e-06	0.000126	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—colon cancer	5.91e-06	0.000126	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—EP300—colon cancer	5.74e-06	0.000122	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—colon cancer	5.67e-06	0.000121	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—colon cancer	5.61e-06	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—colon cancer	5.6e-06	0.000119	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—colon cancer	5.6e-06	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—colon cancer	5.59e-06	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—colon cancer	5.48e-06	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—colon cancer	5.38e-06	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.3e-06	0.000113	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—colon cancer	5.18e-06	0.00011	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—colon cancer	5.15e-06	0.00011	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—colon cancer	5.09e-06	0.000108	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—colon cancer	5.03e-06	0.000107	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—colon cancer	4.89e-06	0.000104	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—colon cancer	4.88e-06	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—colon cancer	4.85e-06	0.000103	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—colon cancer	4.83e-06	0.000103	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—colon cancer	4.77e-06	0.000102	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—colon cancer	4.76e-06	0.000101	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—colon cancer	4.73e-06	0.000101	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—colon cancer	4.67e-06	9.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—colon cancer	4.56e-06	9.71e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EP300—colon cancer	4.5e-06	9.59e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—colon cancer	4.46e-06	9.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—colon cancer	4.44e-06	9.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—colon cancer	4.4e-06	9.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—colon cancer	4.39e-06	9.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—colon cancer	4.38e-06	9.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—colon cancer	4.32e-06	9.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—colon cancer	4.29e-06	9.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—colon cancer	4.27e-06	9.08e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—colon cancer	4.24e-06	9.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—colon cancer	4.21e-06	8.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—colon cancer	4.21e-06	8.96e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—colon cancer	4.1e-06	8.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EP300—colon cancer	4.08e-06	8.7e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—EP300—colon cancer	4.02e-06	8.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—colon cancer	4e-06	8.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—colon cancer	3.97e-06	8.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—colon cancer	3.92e-06	8.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—colon cancer	3.91e-06	8.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—colon cancer	3.89e-06	8.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—colon cancer	3.87e-06	8.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—colon cancer	3.84e-06	8.17e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—colon cancer	3.82e-06	8.13e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—colon cancer	3.82e-06	8.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EP300—colon cancer	3.81e-06	8.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—colon cancer	3.7e-06	7.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—colon cancer	3.63e-06	7.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—colon cancer	3.56e-06	7.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—colon cancer	3.56e-06	7.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—colon cancer	3.55e-06	7.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—colon cancer	3.48e-06	7.41e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—colon cancer	3.47e-06	7.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—colon cancer	3.33e-06	7.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—colon cancer	3.32e-06	7.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—colon cancer	3.31e-06	7.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—colon cancer	3.29e-06	7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—colon cancer	3.25e-06	6.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—colon cancer	3.22e-06	6.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—EP300—colon cancer	3.19e-06	6.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—colon cancer	3.08e-06	6.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—colon cancer	3.07e-06	6.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—colon cancer	3.02e-06	6.43e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—colon cancer	2.97e-06	6.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—colon cancer	2.92e-06	6.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—colon cancer	2.82e-06	6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—colon cancer	2.79e-06	5.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—colon cancer	2.72e-06	5.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—colon cancer	2.61e-06	5.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—colon cancer	2.47e-06	5.25e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—colon cancer	2.43e-06	5.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—colon cancer	2.36e-06	5.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—colon cancer	2.3e-06	4.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—colon cancer	1.93e-06	4.11e-05	CbGpPWpGaD
